News Novartis sets sights on new oral MS drug after phase 3 wins Novartis' oral BTK inhibitor remibrutinib has shown efficacy in a pair of phase 3 trials in multiple sclerosis, boosting its blockbuster credentials.
News Alzheimer's patients 'not changing brain health behaviours' Researchers have found that people with early Alzheimer's are not following guidelines for promoting brain health, even if they are on drug therapy.
News Biogen, Ionis trumpet Alzheimer's data, but shares dip Biogen and Ionis have revealed the first clinical results with tau-targeting Alzheimer's drug candidate diranersen, to a mixed response.
News Bayer's asundexian starts EU review for ischaemic stroke The EMA has started its review of Bayer's asundexian for secondary stroke prevention, keeping it ahead of a rival drug from BMS and J&J.
News AbbVie's migraine drug cleared for migraine attacks on NHS AbbVie's Aquipta can now be commissioned by the NHS in England and Wales as an acute treatment for migraine, after a NICE decision.
News Cellular Intelligence scoops up Novo's Parkinson's therapy Novo Nordisk has sold the rights to one of the flagship candidates in its now-defunct cell therapy unit to AI start-up Cellular Intelligence.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.